Scarica l'app Stockscreener
3.49
4.12%
-0.15
Dopo l'orario di chiusura:
3.49
Precedente Chiudi:
$3.64
Aprire:
$3.62
Volume 24 ore:
310.89K
Relative Volume:
0.89
Capitalizzazione di mercato:
$195.26M
Reddito:
$163.78M
Utile/perdita netta:
$25.88M
Rapporto P/E:
5.3692
EPS:
0.65
Flusso di cassa netto:
$-28.66M
1 W Prestazione:
-1.13%
1M Prestazione:
+12.94%
6M Prestazione:
-47.52%
1 anno Prestazione:
-60.39%
Intervallo 1D:
$3.48
$3.645
Intervallo di 1 settimana:
$3.4644
$3.69
Portata 52W:
$2.75
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Confronta VYGR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.49 | 195.26M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer - Stock Titan
BlackRock, Inc. Reduces Stake in Voyager Therapeutics Inc - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annua - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting | VYGR Stock News - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewswire
Voyager Therapeutics Presents New Data on Tau Silencing Gene Therapy VY1706 and Anti-Amyloid Gene Therapy at ASGCT Annual Meeting - Nasdaq
Revolutionary Alzheimer's Gene Therapy Achieves 73% Tau Reduction: Voyager's Breakthrough Data Revealed - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Decreases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Geode Capital Management LLC Grows Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising Pipeline Developments - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Franklin Resources Inc. Reduces Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Vanguard Group Inc. Grows Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Wellington Management Group LLP Boosts Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
American Century Companies Inc. Has $696,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics stock hits 52-week low at $2.81 - Investing.com
Voyager Therapeutics stock hits 52-week low at $2.81 By Investing.com - Investing.com Canada
Institutional investors may adopt severe steps after Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) latest 15% drop adds to a year losses - simplywall.st
7 Analysts Assess Voyager Therapeutics: What You Need To Know - Benzinga
Voyager Therapeutics chief medical officer sells $34,594 in stock By Investing.com - Investing.com India
Top Executives Unload Thousands of Voyager Therapeutics Shares! - TipRanks
Voyager Therapeutics chief medical officer sells $34,594 in stock - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.54 By Investing.com - Investing.com Philippines
Voyager reveals promising Alzheimer’s therapy data By Investing.com - Investing.com South Africa
Voyager Therapeutics stock hits 52-week low at $3.54 - Investing.com
Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025 - Nasdaq
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - The Manila Times
Voyager reveals promising Alzheimer’s therapy data - Investing.com
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, - GlobeNewswire
Voyager Therapeutics at Virtual CNS Forum: Strategic Insights on Neurotherapeutics - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00 - Armenian Reporter
Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock By Investing.com - Investing.com Canada
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Benzinga
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com Australia
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):